BioSpace News Archive

HOOKIPA Pharma Inc. today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20, in Los Angeles.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will present at the Bank of America Securities 2023 Health Care Conference in Las Vegas, NV, on Thursday, May 11, 2023, at 8:00 am PDT.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023.

Trellis Bioscience Inc announced a clinical proof-of-concept milestone from a planned interim analysis of the company’s Phase 1 trial of its lead antibody, TRL1068, in patients with prosthetic joint infections.

Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended April 2, 2023.

Karuna Therapeutics, Inc. announced financial results for the first quarter of 2023 and provided a general business update.

NanoViricides, Inc., a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D., President of the Company will be presenting at The Inaugural EF Hutton Global Conference, which will be held on May 10-11, 2023, at the Plaza Hotel in the heart of New York City.

NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m.

Protalix BioTherapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update on recent regulatory, clinical and corporate developments.